Table 4.
Summary of studies included in best-case study
| Author | Year | Treatment | Dosage/method of administration |
|---|---|---|---|
| 60 | 1994 | Ginkgo biloba: Extract Egb 761 | 80 mg daily |
| 61 | 2003 | Ginkgo biloba: Extract Egb 761 | 240 mg EGb 761 daily |
| 62 | 1996 | Ginkgo biloba: Extract Egb 761 | 240 mg EGb 761 daily |
| 63 | 1997 | Ginkgo biloba: Extract Egb 761 | 120 mg EGb 761 daily |
| 64 | 1997 | Ginkgo biloba: Extract Egb 761 | 240 mg EGb 761 daily |
| 65 | 1994 | Idebenone | 90 mg daily |
| 66 | 1998 | Idebenone | 90 and 120 mg daily |
| 67 | 1992 | Idebenone | 45 mg daily |
| 68 | 1997 | Idebenone | 30 and 90 mg daily |
| 69 | 1997 | Alpha-tocopherol (vitamin E) | 2000 IU daily |
| 70 | 2003 | Idebenone | 120, 240, or 360 mg Egb 761 daily |
The 11 studies included in the best-case study examining antioxidants (Ginkgo biloba, idebenone and alpha-tocopherol) as a complementary and alternative treatment for AD were then analyzed by an ‘acceptable sampling’ approach.